IL1A and systemic-onset juvenile idiopathic arthritis: The application of biological therapy with the IL-1R inhibitor anakinra, a recombinant form of the human IL-1R antagonist that inhibits IL-1 binding on its receptor approved for use in rheumatoid arthritis, appears to be promising treatment in patietns with refractory Still's disease [2,12-19].